Andrew E. Aplin, PhD
Philadelphia, PA 19107
(215) 923-9248 fax
Most Recent Peer-reviewed Publications
- Co-Targeting HGF/cMET Signaling with MEK Inhibitors in metastatic uveal melanoma
- An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma
- Triple jeopardy for people with albinism
- The melanoma field with dendritic roots
- The state of melanoma: challenges and opportunities
PhD, Biochemistry, Institute of Psychiatry, King's College, London
BSc (Hons), Biochemistry, University of Bath, Department of Biochemistry
Expertise & Research Interests
Malignant melanoma is the deadliest form of skin cancer and its incidence is increasing. Melanoma arises from epidermal melanocytes, the pigment producing cells in the skin. Currently, melanoma metastasis is only preventable by early detection and surgical excision of primary tumors; hence, there is an immediate need to understand the mechanisms underlying melanocyte transformation. We utilize molecular and clinical grade inhibitor approaches to alter key signaling pathway in primary human melanocytes and a panel of melanoma cells characterizing different stages of melanoma progression. We test the role of target proteins in 2D and 3D dermal mimetic in vitro systems and an intradermal in vivo model.
The serine/threonine kinase, B-RAF, is somatically mutated in 50% of melanomas. Mutant B-RAF hyper-activates signaling, which is required for melanoma growth and invasion. One focus in the laboratory is determining the effectors of the mutant B-RAF signaling pathway that elicit malignant traits in melanoma cells. We are identifying mechanisms of pro-survival signaling via alterations in Bcl-2 family proteins and BH-3-only proteins. Additionally, we are investigating the function of Rho family GTPases, epithelial-to-mesenchymal transition (EMT) transcription factors and integrin-mediated signaling in melanoma cell invasion and migration. Other projects are analyzing the signaling pathways downstream of mutant NRAS, which is altered in 15% of melanomas in a manner that is mutually exclusive from B-RAF.
RAF inhibitors have recently been FDA-approved for the treatment of mutant B-RAF melanoma patients. Despite eliciting tumor shrinkage in the majority of patients, approximately 15% of patients do not initially respond and most of the original responders are now eliciting drug resistance. These modes of resistance are major obstacles to the prolonged effects of RAF inhibitor-based therapies. We are elucidating mechanisms of resistance to RAF inhibitors and have focused on FOXD3, a stemness factor. FOXD3 is up-regulated in mutant B-RAF melanoma cells following targeting of the B-RAF-MEK-ERK1/2 signaling pathway and FOXD3 up-regulation provides adaptive drug tolerance to RAF inhibitors. The mechanism of FOXD3 action is an avenue of current investigation. Ultimately, we expect to identify novel strategies for therapeutic intervention in mutant BRAF melanomas.
Melanoma; B-RAF; N-RAS; Tumor microenvironment; Resistance to RAF inhibitors; Rho family GTPases.